Showing results (271-280 of 429) with videos related to
Sort By:
Pageof 43
Annals of Neurology|December 30, 2021
Subcortical Volumes as Early Predictors of Fatigue in Multiple SclerosisVinzenz Fleischer, Dumitru Ciolac, Gabriel Gonzalez-Escamilla, et al.Ebiomedicine|May 28, 2020
Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort studyStefan Bittner, Falk Steffen, Timo Uphaus, et al.Brain, Behavior, and Immunity|November 2, 2022
Factors predisposing to humoral autoimmunity against brain-antigens in health and disease: Analysis of 49 autoantibodies in over 7000 subjectsVinicius Daguano Gastaldi, Justus Bh Wilke, Cosima A Weidinger, et al.Annals of Neurology|October 3, 2009
Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitisJohannes Vogt, Friedemann Paul, Orhan Aktas, et al.Journal of Neuroinflammation|October 8, 2013
Excitotoxic neuronal cell death during an oligodendrocyte-directed CD8+ T cell attack in the CNS gray matterNico Melzer, Gordon Hicking, Stefan Bittner, et al.Journal of Neurology|December 19, 2025
Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimensAgni M Konitsioti, Finja Schweitzer, Wibke Johannis, et al.Plos One|April 25, 2013
Parallelized TCSPC for dynamic intravital fluorescence lifetime imaging: quantifying neuronal dysfunction in neuroinflammationJan Leo Rinnenthal, Christian Börnchen, Helena Radbruch, et al.Neuroimage|January 18, 2015
A human post-mortem brain model for the standardization of multi-centre MRI studiesAmgad Droby, Carsten Lukas, Anne Schänzer, et al.Journal of Neuroinflammation|March 1, 2012
CD4(+) CD25(+) FoxP3(+) regulatory T cells suppress cytotoxicity of CD8(+) effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal levelKerstin Göbel, Stefan Bittner, Nico Melzer, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|March 4, 2015
FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosisFelix Luessi, Stefan Kraus, Bettina Trinschek, et al.Pageof 43